

Beta Thalassemia Market - 2023-2031

<https://marketpublishers.com/r/B716CBE95F06EN.html>

Date: November 2025

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: B716CBE95F06EN

Abstracts

The Beta Thalassemia Market was valued at US\$ 480.32 million in 2023 and is anticipated to reach US\$ 889.04 million by 2031, at a CAGR of 0.081 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Beta Thalassemia Market.

This report delivers a comprehensive overview of the Beta Thalassemia Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Beta Thalassemia Market. The Beta Thalassemia Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Beta Thalassemia Market Scope:

By Type

Beta-Thalassemia Major

Beta-Thalassemia Intermedia

Beta-thalassemia Minor

By Treatment

Iron Chelation Therapy

Folic Acid Supplements

Blood Transfusions

Erythroid Maturation Agents

Stem Cell Transplant

Others

By Route of Administration

Oral

Intravenous

Others

By End Users

Hospitals

Clinics

Others

Key Players

Bristol Myers Squibb

Par Pharmaceuticals

Qilu Pharmaceuticals

Taro Pharmaceuticals

Blue Bird Bio

Cipla Ltd.

Novartis A.G

Teva Pharmaceuticals

Piramal Pharma Solutions

LGM Pharma

Major Highlights

This report delivers a comprehensive overview of the Beta Thalassemia Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Beta Thalassemia Market. The Beta Thalassemia Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by End Users
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Research & Developments and Rising FDA Approvals for Beta Thalassemia
 - 4.1.1.2. Rising Prevalence of Thalassemia
 - 4.1.2. Restraints
 - 4.1.2.1. High Cost of the Treatment
 - 4.1.3. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion

6. BY TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

6.1.2. Market Attractiveness Index, By Type

6.2. Beta-Thalassemia Major

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Beta-Thalassemia Intermedia

6.4. Beta-thalassemia Minor

7. BY TREATMENT

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

7.1.2. Market Attractiveness Index, By Treatment

7.2. Iron Chelation Therapy

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Folic Acid Supplements

7.4. Blood Transfusions

7.5. Erythroid Maturation Agents

7.6. Stem Cell Transplant

7.7. Others

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Oral

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Intravenous

8.4. Others

9. BY END USERS

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

- 9.1.2. Market Attractiveness Index, By End Users
- 9.2. Hospitals
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Clinics
- 9.4. Others

10. BY REGION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
 - 10.2.1. Introduction
 - 10.2.2. Key Region-Specific Dynamics
 - 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
 - 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
 - 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
 - 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.2.7.1. U.S.
 - 10.2.7.2. Canada
 - 10.2.7.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics
 - 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
 - 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
 - 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
 - 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.3.7.1. Germany
 - 10.3.7.2. U.K.
 - 10.3.7.3. France
 - 10.3.7.4. Italy
 - 10.3.7.5. Spain
 - 10.3.7.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.4.7.1. Brazil

10.4.7.2. Argentina

10.4.7.3. Rest of South America

10.5. Asia Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.5.7.1. China

10.5.7.2. India

10.5.7.3. Japan

10.5.7.4. South Korea

10.5.7.5. Rest of Asia Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario

11.2. Product Benchmarking

- 11.3. Company Share Analysis
- 11.4. Key Developments and Strategies

12. COMPANY PROFILES

- 12.1. Bristol Myers Squibb*
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio and Description
 - 12.1.3. Financial Overview
 - 12.1.4. Key Developments
- 12.2. Par Pharmaceuticals
- 12.3. Qilu Pharmaceuticals
- 12.4. Taro Pharmaceuticals
- 12.5. Blue Bird Bio
- 12.6. Cipla Ltd.
- 12.7. Novartis A.G
- 12.8. Teva Pharmaceuticals
- 12.9. Piramal Pharma Solutions
- 12.10. LGM Pharma (LIST NOT EXHAUSTIVE)

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

I would like to order

Product name: Beta Thalassemia Market - 2023-2031

Product link: <https://marketpublishers.com/r/B716CBE95F06EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B716CBE95F06EN.html>